KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
KUBOTA PHARMACEUTICAL HOLDINGS CO LTD (ACUC): 3 pipeline candidates · ~41 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
41.1 months
0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for KUBOTA PHARMACEUTICAL HOLDINGS CO LTDacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$12.2M
Quarterly Burn
$8.1M
Runway
41.1 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| acu-6151 | Preclinical |
| emixustat | Phase 2 |
| lanosterol | Preclinical |
Frequently asked questions
How many drug candidates are in KUBOTA PHARMACEUTICAL HOLDINGS CO LTD's pipeline?
KUBOTA PHARMACEUTICAL HOLDINGS CO LTD (ACUC) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is KUBOTA PHARMACEUTICAL HOLDINGS CO LTD's lead drug candidate?
KUBOTA PHARMACEUTICAL HOLDINGS CO LTD's most advanced tracked candidate is acu-6151 (Preclinical) for neovascular retinal diseases such as wet age related macular degeneration, diabetic retinopathy / diabetic macular edema and retinal vein occlusion.
What is KUBOTA PHARMACEUTICAL HOLDINGS CO LTD's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, KUBOTA PHARMACEUTICAL HOLDINGS CO LTD has approximately 41.1 months of cash runway.
Who is the CEO of KUBOTA PHARMACEUTICAL HOLDINGS CO LTD?
Board Table is the chief executive officer of KUBOTA PHARMACEUTICAL HOLDINGS CO LTD (ACUC).
Get the full picture on KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.